Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study

Preliminary retrospective pilot data only — no actionable change to prescribing practice is warranted until controlled prospective studies are completed.